BAYN Stock Overview
Operates as a life science company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 1/6 |
Bayer Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €19.84 |
| 52 Week High | €35.22 |
| 52 Week Low | €19.15 |
| Beta | 1 |
| 11 Month Change | -26.65% |
| 3 Month Change | n/a |
| 1 Year Change | -39.36% |
| 33 Year Change | -56.97% |
| 5 Year Change | n/a |
| Change since IPO | -60.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| BAYN | BG Pharmaceuticals | BG Market | |
|---|---|---|---|
| 7D | -2.8% | 3.0% | -0.5% |
| 1Y | -39.4% | 5.7% | 9.9% |
Return vs Industry: BAYN underperformed the BG Pharmaceuticals industry which returned 5.7% over the past year.
Return vs Market: BAYN underperformed the BG Market which returned 9.9% over the past year.
Price Volatility
| BAYN volatility | |
|---|---|
| BAYN Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in BG Market | 7.6% |
| 10% least volatile stocks in BG Market | 2.6% |
Stable Share Price: BAYN's share price has been volatile over the past 3 months compared to the BG market.
Volatility Over Time: Insufficient data to determine BAYN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1863 | 94,245 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
| BAYN fundamental statistics | |
|---|---|
| Market cap | €19.45b |
| Earnings (TTM) | -€880.00m |
| Revenue (TTM) | €46.74b |
0.4x
P/S Ratio-22.1x
P/E RatioIs BAYN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAYN income statement (TTM) | |
|---|---|
| Revenue | €46.74b |
| Cost of Revenue | €20.03b |
| Gross Profit | €26.71b |
| Other Expenses | €27.59b |
| Earnings | -€880.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 05, 2025
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 57.15% |
| Net Profit Margin | -1.88% |
| Debt/Equity Ratio | 134.1% |
How did BAYN perform over the long term?
See historical performance and comparison